Baxter: Four-year Study Indicates Approx. 25% Lower Mortality With Use Of Theranova Dialyzer
(RTTNews) - Baxter International (BAX) announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis. The new data is from a 48-month observational cohort study involving 1,092 dialysis patients at 11 Baxter Renal Care Services Centers in Colombia.
"It is very exciting to see the results of this four-year study, indicating approximately 25% lower mortality for chronic kidney patients with the use of Baxter's Theranova dialyzer," said Peter Rutherford, vice president, Medical Affairs, Kidney Care, Baxter.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.